Trusted DMD news and updates

Where to follow reliable DMD and BMD news without chasing every headline.

news-trusted-cover-16x9

DMD news moves quickly. A single headline can mix early laboratory work, a small clinical trial, and a approved treatment in the same sentence. DMD Panda curates updates with that context in mind.

We point families to organizations that publish clear, sourced information. The World Duchenne Organization shares global research and care updates. Parent Project Muscular Dystrophy publishes research, care, and advocacy news for the United States. Duchenne UK and Action Duchenne publish updates for the United Kingdom.

When you read a new claim, ask three questions: What stage is this at? Who was studied? Has a regulator approved it? A promising laboratory result is not the same as an approved medicine.

DMD Panda does not replace those organizations or your care team. We summarize what is useful and link to the original source so you can read the full detail.

This page is for general information only and is not medical advice.

DMD PIPELINE WATCH — NOVEMBER 2026
Published 12 November 2026. This is a public-source brief, not medical or investment advice.
SCOPE AND METHOD We included 15 companies with a publicly disclosed clinical or marketed DMD/BMD therapeutic programme on their official website or in an official press release, checked on 12 November 2026. Preclinical-only programmes and companies that have discontinued or divested their DMD assets are excluded. Avidity Biosciences is now part of Novartis. Edgewise Therapeutics' sevasemten programme is now with Servier. PepGen discontinued its PGN-EDO51 DMD programme in 2025 and is not listed. Catalyst Pharmaceuticals is now part of Angelini Pharma; its US AGAMREE role is noted under Santhera.
PIPELINE COMPANIES (15)
  1. Sarepta Therapeutics (United States) Assets: ELEVIDYS (delandistrogene moxeparvovec) gene therapy; EXONDYS 51 (eteplirsen), VYONDYS 53 (golodirsen) and AMONDYS 45 (casimersen) exon-skipping therapies. Stage: approved in the US; the ELEVIDYS label is limited to ambulatory patients. Official pipeline: https://www.sarepta.com/products-pipeline/pipeline
  1. Roche (Switzerland) Assets: ELEVIDYS outside the US; a new Phase III study in early ambulatory DMD. Stage: approved in some markets; Phase III ongoing. Official pipeline: https://www.roche.com/solutions/pipeline
  1. PTC Therapeutics (United States) Assets: EMflaza (deflazacort); Translarna (ataluren) for nonsense-mutation DMD outside the US. Stage: marketed; availability varies by country. Official DMD page: https://www.ptcbio.com/therapeutic-areas/duchenne-muscular-dystrophy/
  1. NS Pharma / Nippon Shinyaku (Japan and United States) Assets: VILTEPSO (viltolarsen, exon 53); brogidirsen (NS-089/NCNP-02, exon 44). Stage: VILTEPSO approved; brogidirsen in clinical development. Official pipeline: https://www.nspharma.com/pipeline-products/
  1. Wave Life Sciences (United States) Assets: WVE-N531 (exon 53). Stage: Phase 1b/2; the company plans an NDA in 2026. Official pipeline: https://www.wavelifesciences.com/pipeline/
  1. Dyne Therapeutics (United States) Assets: z-rostudirsen (DYNE-251, exon 51); preclinical DYNE-244, DYNE-245, DYNE-253 and DYNE-255 (exons 44, 45, 53 and 55). Stage: BLA under priority review; PDUFA target date 21 January 2027. Official pipeline: https://www.dyne-tx.com/pipeline/
  1. Novartis (Switzerland; formerly Avidity Biosciences) Assets: del-zota (delpacibart zotadirsen, exon 44). Stage: BLA under priority review; Avidity acquisition closed in February 2026. Official pipeline: https://www.novartis.com/research-development/novartis-pipeline
  1. Entrada Therapeutics (United States) Assets: ENTR-601-44, ENTR-601-45, ENTR-601-50 and ENTR-601-51. Stage: ENTR-601-44 and -45 in Phase 1/2; -50 and -51 at earlier stages. Official pipeline: https://www.entradatx.com/pipeline
  1. Solid Biosciences (United States) Assets: SGT-003 gene therapy. Stage: Phase 1/2 INSPIRE DUCHENNE and Phase 3 IMPACT DUCHENNE. Official pipeline: https://www.solidbio.com/our-science/pipeline-programs/pipeline/
  1. REGENXBIO (United States) Assets: RGX-202 gene therapy. Stage: late-stage development; BLA submission planned for Q1 2027. Official pipeline: https://www.regenxbio.com/therapeutic-programs/
  1. Capricor Therapeutics (United States) Assets: deramiocel (CAP-1002), a cell therapy for DMD cardiomyopathy and skeletal muscle function. Stage: BLA under FDA review; PDUFA target date 22 November 2026. Official DMD page: https://www.capricor.com/pipeline/duchenne-muscular-dystrophy-overview
  1. Italfarmaco (Italy) Assets: givinostat (Duvyzat), an HDAC inhibitor for DMD. Stage: approved in the US; marketed as Duvyzat. Official portfolio: https://www.italfarmaco.com/portfolio/
  1. Santhera Pharmaceuticals (Switzerland) Assets: AGAMREE (vamorolone), a dissociative corticosteroid for DMD. Stage: approved in multiple markets; US rights are held by Catalyst, now part of Angelini Pharma. Official DMD page: https://www.santhera.com/patients/our-research/duchenne-muscular-dystrophy
  1. Servier (France) Assets: sevasemten (acquired from Edgewise Therapeutics). Stage: Phase 3 in Becker muscular dystrophy did not meet its primary endpoint in November 2026; a separate Phase 2 DMD study is ongoing. Official release: https://servier.com/newsroom/resultats-principaux-etude-pivot-sevasemten-becker/
  1. Genethon (France; nonprofit) Assets: GNT0004 gene therapy. Stage: Phase 1/2/3. Official DMD pipeline: https://www.genethon.com/our-pipeline/duchenne-muscular-dystrophy/
NOVEMBER 2026 PRESS RELEASES (9) These are English summaries written by DMD Panda. We do not reproduce the full articles or their images. Each link goes to the company's original release.
  1. Servier: Phase 3 sevasemten study misses primary endpoint in Becker muscular dystrophy Date: 3 November 2026 Summary: Servier said the 18-month Phase 3 GRAND CANYON trial did not meet its primary NSAA endpoint or its secondary endpoints. The safety profile remained favourable, and the company said it is analysing the full dataset. Sevasemten is also in a separate Phase 2 DMD study. Original (French): https://servier.com/newsroom/resultats-principaux-etude-pivot-sevasemten-becker/
  1. Italfarmaco: givinostat wins Prix Galien Italia rare-disease award Date: 4 November 2026 Summary: Italfarmaco said givinostat received the 2026 Prix Galien Italia award in the rare-diseases category. The company described the HDAC inhibitor, used with corticosteroids, as a mutation-independent DMD treatment option. Original: https://www.italfarmaco.com/Press-Review-PDF/Prix_Galien_Italia_2026_%20news%20release_def.pdf
  1. Solid Biosciences: SGT-003 tolerated in 53 participants; FDA Type C meeting planned Date: 4 November 2026 Summary: Solid said SGT-003 was generally well tolerated in 53 participants in the Phase 1/2 INSPIRE DUCHENNE trial as of 3 November 2026. It plans a Type C FDA meeting in late Q4 2026 on a potential accelerated-approval pathway, while the Phase 3 IMPACT trial continues. Original: https://investors.solidbio.com/news-releases/news-release-details/solid-biosciences-reports-third-quarter-2026-financial-results
  1. Sarepta: Q3 2026 revenue and updated ELEVIDYS data Date: 5 November 2026 Summary: Sarepta reported Q3 2026 net product revenue of
    323.8million,including323.8 million, including
    
    83.5 million from ELEVIDYS. It said the ambulatory-only ELEVIDYS label continued to affect sales and presented two-year data in ambulatory patients at the 2026 World Muscle Society congress. Original: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2026-financial
  1. Dyne: z-rostudirsen BLA under priority review, PDUFA 21 January 2027 Date: 5 November 2026 Summary: Dyne said the FDA is reviewing z-rostudirsen for exon 51 DMD under priority review, with a PDUFA target date of 21 January 2027. It is also advancing four preclinical candidates for exons 44, 45, 53 and 55. Original: https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-third-quarter-2026-financial-results
  1. REGENXBIO: RGX-202 BLA planned for Q1 2027 Date: 5 November 2026 Summary: REGENXBIO said RGX-202 remains on track for a BLA submission in Q1 2027 under accelerated approval, with potential approval in the second half of 2027. A pre-BLA FDA meeting is expected in Q4 2026. Original: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-reports-third-quarter-2026-financial-results-and
  1. Entrada: DMD exon-skipping programmes advance Date: 5 November 2026 Summary: Entrada said open-label Cohort 1 data for ENTR-601-44 are expected by the end of 2026, with Cohort 2 data in Q1 2027. Its DMD programmes target exons 44, 45, 50 and 51. Original: https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-reports-third-quarter-2026-financial
  1. Capricor: HOPE-3 cardiac data receive AHA award Date: 9 November 2026 Summary: Capricor said HOPE-3 cardiac results for deramiocel received the American Heart Association's Outstanding Research Award in Pediatric Cardiology. In the 106-patient trial, the key secondary LVEF endpoint in all patients did not reach statistical significance (p=0.09); the cardiomyopathy subgroup showed a +2.8 percentage-point difference. Original: https://www.capricor.com/investors/news-events/press-releases/detail/358/capricors-hope-3-phase-3-cardiac-results-for-deramiocel
  1. Capricor: deramiocel BLA under review, PDUFA 22 November 2026 Date: 10 November 2026 Summary: Capricor said its deramiocel BLA for DMD is under FDA review with a PDUFA target date of 22 November 2026. It proposed a refined indication focused on upper-limb impairment in patients older than 9. Original: https://www.capricor.com/investors/news-events/press-releases/detail/359/capricor-therapeutics-reports-third-quarter-2026-financia
WHAT TO KEEP IN MIND Pipeline stages, labels and regulatory dates change. A press release is a company statement, not independent confirmation or medical advice. Families should confirm current approval, trial eligibility and safety information with the company, a specialist care team or a recognised DMD organisation.
This page is for general information only and is not medical advice.

Read next

More from the journal

Keep readers moving through related announcements, stories, and field notes.